This post is presented by our media partner Psychedelic News Wire
View the original article here.
It seems that an increasing number of mothers in the United States are microdosing psychedelics to help them cope with the stresses of motherhood. As a growing body of research indicates that psychedelics may be effective mental-health treatments, the trend of microdosing psychedelics, specifically among moms, has been on the rise.
These studies may be the first official efforts to fully research psychedelics and their potential benefits, but they have been incredibly encouraging so far, indicating that hallucinogenics could help treat various mental health conditions that typically don’t react to conventional medications. Microdosing psychedelics means taking small amounts of hallucinogens, such as psilocybin, to enjoy the mental-health benefits without experiencing a psychedelic trip.
According to Harvard Health, a microdose measures anywhere from 1/20th to 1/10th of the standard dose of a psychedelic.
Anecdotal reports from mothers across the country indicate that psychedelics help them cope with anxiety and stress while limiting their medication and alcohol intake. An organization called Moms on Mushrooms is working to destigmatize psychedelic use by moms via conversation and education. The organization supports safe microdosing by moms to help them cope with stress as well as heal and grow, and the group believes that moms across the country can “come together” through the use of psychedelics.
The San Francisco Bay area is one of the many places in the country experiencing a psychedelic renaissance. Many moms living in such locations are becoming more comfortable discussing psychedelic use and even using small amounts of psychedelics.
Melissa Whippo, a licensed clinical social worker with close to two decades of experience counseling pregnant and postpartum women, says she has spoken to several women in the Bay Area who confess to using psychedelics to treat depression, trauma and anxiety. They feel that psychedelics such as psilocybin are safer because they are “natural” and do not have to be taken every day, such as conventional medications, including Prozac.
However, while some physicians say psychedelics can be a better alternative to taking pills, others have cautioned against the habit and argued that it is a fad that will soon die down. Dr. Daniel Amen, for instance, is a brain disorder specialist and psychiatrist with four decades of experience treating mental disorders; he believes the microdosing psychedelics fad will not last. Furthermore, he explained that the fad will cause problems because there simply isn’t enough scientific data on the safety and effectiveness of self-administering psychedelics.
Such user habits create an urgency for enterprises such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to develop approved health and wellness products so that members of the public can benefit from psychedelics without taking undue risks.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
This post was originally published by our media partner here.
